No Data
Guggenheim Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $800
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), PepGen Inc. (PEPG) and Omeros (OMER)
Jefferies Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Raises Target Price to $525
Jefferies Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Praxis Precision Medicines Shares Are Trading Higher After the FDA Accepted for Priority Review the Company's New Drug Application for Relutrigine, for the Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies